The biotech industry includes bio-pharma, bio-services, bio-agri, bio-industrials and bioinformatics. Biopharma is a rapidly growing segment that accounts for a dominant share in this sector. Advancements in biotechnology have enabled researchers to evaluate and identify target biomarkers/cell receptors to develop targeted and personalized therapies. Scientific research and technological advancements have resulted in the emergence of various personalized medicines that are undergoing research. According to research conducted by the Personalized Medicine Coalition, 42% of all compounds and 73% of oncology compounds in the pipeline possess the potential to be personalized medicine. Moreover, according to this study, it is expected that companies will increase their investment in R&D of personalized medicines by 1/3rd over the following five years. The study found that over 20% of drugs approved in 2014 were personalized medicines.
The biotechnology sector has witnessed some disruptive innovations such as gene and cell therapies, immunotherapy, and antibody drug conjugates. Advancement in stem cell therapy is resulting in effective treatment therapies for chronic conditions, organ growth and repair and disease prevention.
Biotech products have extensive application in oncology and autoimmune disease treatment. However, the cost of these drugs is high owing to extensive research and trials that need to be carried out for the same. Therefore, there is constant pressure to reduce price and increase accessibility, especially in emerging economies. In the U.S., companies are facing reimbursement issues with respect to biopharmaceutical products. Besides, there are regulatory and scientific challenges faced by the sector. Scientific research for new molecules and targeted therapies is capital intensive and challenging owing to growing concern for safety of the drug.
Also, there is lack of awareness about personalized medicine among most healthcare providers, which may hamper its adoption. Clinical adoption of biotechnology products is essential for its success. However, it significant scientific evidence and backing is required to ensure its safety.
“Translating genomic discoveries into personalized medicines entails overcoming substantial scientific, regulatory, and economic challenges, including identifying validated biomarkers, as well as developing personalized therapeutics and clinically relevant diagnostic tests.”
The biopharmaceutical sector offers vast lucrative growth opportunities. High efficacy and safety of biopharmaceutical products has led to a growth in their demand, Furthermore, consumers are willing to pay high prices for biopharmaceutical products compared to other conventional products. Biopharmaceutical brands have set new standards for blockbuster drugs by recording an annual average sale of over US$ 2bn. Drugs such as Humira have generated sales revenue of over US$ 10bn.
Governments in emerging economies are endorsing biosimilars as cost-effective alternatives to biotech products, which is expected to create significant growth opportunities for manufacturers of generic drugs. Therefore, cost-effectiveness and high quality are prime parameters that need to be considered while developing biosimilars. Recent and upcoming biologic patent expirations include the following:
Companies such as Teva Pharmaceuticals, Hospira, Sandoz, and Amgen are focusing on development of biosimilars and vaccines as preventive measures in addition to treatment. For instance, in 2015, Zarxio TM became the first biosimilar to be approved in the U.S. market. The EMA approved Mosquirix, a malaria vaccine, in the same year. Extensive research is currently underway to develop a dengue vaccine, which could be another breakthrough pharmaceutical product in the near future.
The increasing research in the biotechnology sector is expected to result in higher number of biopharmaceutical products seeking FDA approvals. Biopharmaceuticals are positioned to be promising treatment solutions that would improve patient outcomes and help with reduction of the cost of drug development.
The global biopharmaceuticals market was valued at US$ 371.26 Bn in 2022 and is forecast to reach a value of US$ 654.76 Bn by 2030 at a CAGR of 7.4% ... View more
The global bioengineered artificial skin market was valued at US$ 3.16 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 21.5% to reach US$ 15.00 billion by end of 2030. Factors such a... View more
The global transfection reagents and equipment market was valued at US$ 1,066.5 Mn in 2022 and is forecast to reach a value of US$ 2,171.7 Mn by 2030 at a CAGR of 9.3% ... View more
The global virus filtration market was valued at US$ 4,441.2 Mn in 2022 and is forecast to reach a value of US$ 12,920.5 Mn by 2030 at a CAGR of 14.3% between ... View more
Global ribonucleic acid (RNA) markers market is estimated to be valued at US$ 226.6 million in 2023 and is expected to exhibit a CAGR of 8.76% during the forecast period (2023-2030). ... View more
The global cell surface markers detection market was valued at US$ 5,019.5 Mn in 2022 and is forecast to reach a value of US$ 10,087.6 Mn by 2030 at a CAGR of 9.17%&... View more
Global m-RNA synthesis service market is estimated to be valued at US$ 6,438.6 Million in 2023 and is expected to exhibit a CAGR of 5.57% during the forecast period (2023-2030). Incre... View more
Bovine plasma is prepared from pooled bovine blood. It is prepared from the whole blood, which contains anticoagulant, cells, and other blood contents. Then it is centrifuged to remove cells and cellular debris. It contains 3.8% trisodium citrate as an anticoagulant. ... View more
Proteins are manufactured under guidelines that allow for their use as ancillary materials in cell therapy or further manufacturing processes. GMP proteins also come with extensive documentation and traceability, as well as additional quality control testing. Global G... View more
The global cell therapy market was valued at US$ 786.50 Mn in 2022 and is forecast to reach a value of US$ 1,391.94 Million by 2030 at a CAGR of 7.4% between ... View more
The global stem cell manufacturing market was valued at US$ 8,584.2 Mn in 2021 and is forecast to reach a value of US$ 20,428.1 Mn by 2028 at a CAGR of 13.3% between... View more
The global single-use bioreactor market was valued at US$ 1,001.0 Mn in 2021 and is forecast to reach a value of US$ 2,768.3 Mn by 2028 at a CAGR of 15.6% betwe... View more
PEGylation, a technique to get around some of the drawbacks of some biopharmaceuticals, is the term used to describe the alteration of biological molecules by covalent conjugation with polyethylene glycol (PEG), a non-toxic, non-immunogenic polymer. PEGylation improve... View more
Newborn Calf Serum (NBCS) is developed from 3 to 10 days old calves. NBCS is cheaper and better in quality than fetal bovine serum. As newborn calf serum (NBCS) is more affordable and commonly available, it is preferred as a basal growth medium over fetal ... View more
Pulmonary surfactant is a complex mixture of phospholipids and proteins that creates a unique interface separating alveolar gas and liquids at the alveolar cell surface, reducing surface tension, and maintaining lung volumes at end expiration. Reduction of the surface... View more
Clostridium difficile is a causative agent for various gut disorders with symptoms such as diarrhea, nausea, colon inflammation, and others. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as ... View more
Temperature is one of the vital signs signifying the well-being of a person, for which the medical society recommends monitoring and management, as a part of standard care therapy for patients undergoing surgery due to critical illness. Patient temperature monitoring ... View more
The global human embryonic stem cells market was valued at US$ 1,058.9 Mn in 2021 and is forecast to reach a value of US$ 1,955.3 Mn by 2028 at a CAGR of 9.2% betwee... View more
The global protein engineering market was valued at US$ 1,936.7 Mn in 2021 and is forecast to reach a value of US$ 5,355.8 Mn by 2028 at a CAGR of 15.6% between ... View more
Research antibodies act as vital tools in laboratory techniques such as western blotting etc. that are conducted for research purposes. Due to their high specificity and sensitivity, antibodies and associated reagents make an important tool that aids in the detection ... View more